股本结构
单位：万股
| 公告日期 | 2025-11-10 | 2025-11-10 | 2025-08-15 | 2025-08-06 | 2025-08-06 | 2025-05-08 |
|---|---|---|---|---|---|---|
| 证券总股本 | 1581.71 | 1581.70 | 1556.00 | 767.23 | 767.22 | 761.89 |
| 普通股本 | 1581.71 | 1581.70 | 1556.00 | 767.23 | 767.22 | 761.89 |
| 优先股 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 其他 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 | 未披露 |
| 变动日期 | 2025-11-07 | 2025-09-30 | 2025-08-08 | 2025-08-01 | 2025-06-30 | 2025-03-31 |
注释：中概股证券总股本=普通股股本/
存托凭证比例
历史变动
| 公告日期 | 变动后普通股本（万股） | 变动后优先股（万股） | 变动原因 | 变动日期 |
|---|---|---|---|---|
| 2025-11-10 | 1581.71 | 未披露 | 定期报告 | 2025-11-07 |
| 2025-11-10 | 1581.70 | 未披露 |
更多>>
From June 30,2025 to September 30,2025
Issuance of common stock upon exercise of stock options
Issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs
Issuance of common stock upon exercise of warrants
Issuance of common stock for settlement of restricted stock units (RSUs)
Issuance of common stock and warrants in a private placement to a related party, net of issuance costs
|
2025-09-30 |
| 2025-08-15 | 1556.00 | 未披露 | 定期报告 | 2025-08-08 |
| 2025-08-06 | 767.23 | 未披露 | 定期报告 | 2025-08-01 |
| 2025-08-06 | 767.22 | 未披露 |
更多>>
From March 31, 2025 to June 30, 2025
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of common stock for settlement of restricted stock units (RSUs)
|
2025-06-30 |
| 2025-04-23 | 763.76 | 未披露 | 定期报告 | 2025-04-08 |
| 2025-05-08 | 761.89 | 未披露 |
更多>>
From December 31, 2024 to March 31, 2025
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
|
2025-03-31 |
| 2025-03-20 | 750.34 | 未披露 | 定期报告 | 2025-03-14 |
| 2025-03-20 | 745.72 | 未披露 |
更多>>
From December 31, 2023 to December 31, 2024
Issuance of common stock under ATM equity offering program, net of issuance costs
Issuance of common stock and warrants in private placements to a related party, net of issuance costs
Issuance of common stock for settlement of RSUs
Issuance of common stock and warrants in a registered direct offering, net of issuance costs
Issuance of common stock upon exercise of stock options
Issuance of common stock under ESPP
|
2024-12-31 |
| 2024-11-07 | 635.63 | 未披露 | 定期报告 | 2024-11-01 |
| 2024-11-07 | 635.44 | 未披露 |
更多>>
From June 30, 2024 to September 30, 2024
Issuance of common stock for settlement of restricted stock units (RSUs)
|
2024-09-30 |
| 2024-08-08 | 634.56 | 未披露 |
更多>>
From March 31, 2024 to June 30, 2024
Issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs
Issuance of common stock for settlement of restricted stock units (RSUs)
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of common stock upon exercise of stock options
|
2024-06-30 |
| 2024-06-18 | 634.56 | 未披露 |
更多>>
1.Common stock offered 634,500 shares by the company
2.On June 17, 2024, Assembly Biosciences, Inc. entered into a Securities Purchase Agreement with Gilead Sciences, Inc. for the issuance and sale, in a private placement, of 179,500 shares of the Company’s common stock
|
2024-06-17 |
| 2024-06-18 | 553.16 | 未披露 | 定期报告 | 2024-06-14 |
| 2024-05-08 | 551.33 | 未披露 | 定期报告 | 2024-05-03 |
| 2024-05-08 | 548.28 | 未披露 | 定期报告 | 2024-03-31 |
| 2024-03-28 | 548.28 | 未披露 |
更多>>
Assembly Biosciences, Inc. today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024. The company anticipates that its common stock will begin trading on a split-adjusted basis on The Nasdaq Global Select Market under the same symbol when the market opens on February 12, 2024.
|
2024-02-12 |
| 2023-12-21 | 6579.34 | 未披露 | 定期报告 | 2023-12-08 |
| 2023-11-08 | 6570.91 | 未披露 | 定期报告 | 2023-11-03 |
| 2023-11-08 | 5261.42 | 未披露 |
更多>>
From June 30, 2023 to September 30, 2023
Issuance of common stock for settlement of restricted stock units (RSUs)
|
2023-09-30 |
| 2023-08-09 | 5261.42 | 未披露 | 定期报告 | 2023-08-04 |
| 2023-08-09 | 5245.07 | 未披露 |
更多>>
From March 31, 2023 to June 30, 2023
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
Issuance of common stock for settlement of restricted stock units (RSUs)
|
2023-06-30 |
| 2023-05-04 | 5212.13 | 未披露 | 定期报告 | 2023-05-01 |
| 2023-05-04 | 5201.53 | 未披露 |
更多>>
From December 31, 2022 to March 31, 2023
Issuance of common stock for settlement of restricted stock units (RSUs)
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
|
2023-03-31 |
| 2023-03-22 | 5194.69 | 未披露 | 定期报告 | 2023-03-20 |
| 2023-03-22 | 4889.50 | 未披露 |
更多>>
From December 31, 2021 to December 31, 2022
Issuance of common stock under ATM equity offering program, net of issuance costs
Issuance of common stock under ESPP
Issuance of common stock for settlement of RSUs
|
2022-12-31 |
| 2022-11-08 | 4878.00 | 未披露 | 定期报告 | 2022-11-03 |
| 2022-11-08 | 4848.12 | 未披露 |
更多>>
From June 30, 2022 to September 30, 2022
Issuance of common stock for settlement of restricted stock units (RSUs)
|
2022-09-30 |
| 2022-08-09 | 4843.69 | 未披露 | 定期报告 | 2022-08-04 |
| 2022-08-09 | 4836.27 | 未披露 |
更多>>
From March 31, 2022 to June 30, 2022
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of common stock for settlement of restricted stock units (RSUs)
|
2022-06-30 |
| 2022-05-12 | 4821.65 | 未披露 | 定期报告 | 2022-05-09 |
| 2022-05-12 | 4813.29 | 未披露 |
更多>>
From December 31, 2021 to March 31, 2022
Issuance of common stock for settlement of restricted stock units (RSUs)
|
2022-03-31 |
| 2022-03-11 | 4812.04 | 未披露 |
更多>>
From December 31, 2020 to December 31, 2021
Issuance of common stock under ATM equity offering program, net of issuance costs
Issuance of common stock under ESPP
Issuance of common stock for settlement of RSUs
Issuance of common stock upon cashless exercise of pre-funded warrants
|
2021-12-31 |
| 2021-11-04 | 4786.17 | 未披露 | 定期报告 | 2021-11-01 |
| 2021-11-04 | 4707.71 | 未披露 |
更多>>
From June 30, 2021 to September 30, 2021
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
Issuance of common stock upon cashless exercise of pre-funded warrants
Issuance of common stock for settlement of restricted stock units (RSUs)
|
2021-09-30 |
| 2021-08-05 | 4497.16 | 未披露 | 定期报告 | 2021-08-02 |
| 2021-08-05 | 4377.91 | 未披露 |
更多>>
From March 31, 2021 to June 30, 2021
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
Issuance of common stock under ESPP
Issuance of common stock for settlement of restricted stock units (RSUs)
Issuance of common stock upon cashless exercise of pre-funded warrants
|
2021-06-30 |
| 2021-05-06 | 4015.82 | 未披露 | 定期报告 | 2021-05-03 |
| 2021-05-06 | 4010.47 | 未披露 |
更多>>
from December 31, 2020 to March 31, 2021
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
|
2021-03-31 |
| 2021-04-07 | 4005.91 | 未披露 | 定期报告 | 2021-03-23 |
| 2021-02-25 | 3824.61 | 未披露 | 定期报告 | 2021-02-22 |
| 2021-02-25 | 3402.67 | 未披露 |
更多>>
From December 31,2019 to December 31,2020
Issuance of common stock upon exercise of stock options
Issuance of shares of common stock for settlement of RSUs
Sale of common stock, net of commissions and fees
Issuance of common stock under ESPP
|
2020-12-31 |
| 2020-11-05 | 3302.23 | 未披露 | 定期报告 | 2020-11-02 |
| 2020-11-05 | 3292.45 | 未披露 |
更多>>
From June 30, 2020 to September 30, 2020
Issuance of common stock upon exercise of stock options
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
|
2020-09-30 |
| 2020-08-05 | 3285.49 | 未披露 | 定期报告 | 2020-08-03 |
| 2020-08-05 | 3280.75 | 未披露 |
更多>>
From March 31, 2020 to June 30, 2020
Issuance of common stock upon exercise of stock options
Issuance of common stock under ESPP
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
|
2020-06-30 |
| 2020-05-08 | 3272.24 | 未披露 | 定期报告 | 2020-05-04 |
| 2020-04-27 | 3270.73 | 未披露 | 定期报告 | 2020-04-13 |
| 2020-05-08 | 3262.47 | 未披露 |
更多>>
From December 31, 2019 to March 31, 2020
Issuance of common stock upon exercise of stock options
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
|
2020-03-31 |
| 2020-03-04 | 3262.47 | 未披露 | 定期报告 | 2020-03-02 |
| 2020-03-04 | 3255.83 | 未披露 |
更多>>
from December 31, 2018 to December 31, 2019
Sale of common stock and pre-funded warrants, net of underwriters' discount and costs
Issuance of common stock upon exercise of stock options
Issuance of common stock under ESPP
Issuance of shares of common stock for settlement of RSUs
|
2019-12-31 |
| 2019-12-16 | 3216.06 | 未披露 |
更多>>
Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 6,287,878 shares of its common stock to the public at $16.50 per share, which included the exercise in full by the underwriters of their option to purchase 1,136,363 additional shares of common stock.
|
2019-12-16 |
| 2019-11-07 | 2604.70 | 未披露 | 定期报告 | 2019-11-04 |
| 2019-11-07 | 2587.27 | 未披露 |
更多>>
from June 30, 2019 to September 30, 2019
Issuance of common stock upon exercise of stock options
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
|
2019-09-30 |
| 2019-08-05 | 2571.18 | 未披露 | 定期报告 | 2019-07-31 |
| 2019-08-05 | 2564.68 | 未披露 |
更多>>
From March 31, 2019 to June 30, 2019
Issuance of common stock upon exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
|
2019-06-30 |
| 2019-05-09 | 2560.10 | 未披露 | 定期报告 | 2019-05-06 |
| 2019-05-09 | 2554.98 | 未披露 |
更多>>
from December 31, 2018 to March 31, 2019
Proceeds from the exercise of stock options
Issuance of shares for settlement of restricted stock units
|
2019-03-31 |
| 2019-04-04 | 2554.98 | 未披露 | 定期报告 | 2019-03-22 |
| 2019-02-28 | 2554.08 | 未披露 | 定期报告 | 2019-02-25 |
| 2019-02-28 | 2549.54 | 未披露 |
更多>>
from December 31, 2017 to December 31, 2018
Proceeds from common stock sold, net of underwriters' discounts and cost
Proceeds from the exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Settlement of restricted stock units into common stock
|
2018-12-31 |
| 2018-11-08 | 2546.32 | 未披露 | 定期报告 | 2018-11-05 |
| 2018-11-08 | 2546.01 | 未披露 |
更多>>
from December 31, 2017 to September 30, 2018
Proceeds from common stock sold, net of underwriters' discounts and cost
Proceeds from the exercise of stock options
Settlement of restricted stock units into common stock
|
2018-09-30 |
| 2018-08-08 | 2544.65 | 未披露 | 定期报告 | 2018-08-07 |
| 2018-08-08 | 2061.45 | 未披露 |
更多>>
from December 31, 2017 to June 30, 2018
Proceeds from the exercise of stock options
|
2018-06-30 |
| 2018-05-07 | 2055.07 | 未披露 | 定期报告 | 2018-05-02 |
| 2018-04-19 | 2042.94 | 未披露 | 定期报告 | 2018-04-05 |
| 2018-05-07 | 2038.67 | 未披露 |
更多>>
From December 31, 2017 to March 31, 2018
Proceeds from the exercise of stock options
|
2018-03-31 |
| 2018-03-08 | 2025.13 | 未披露 | 定期报告 | 2018-03-05 |
| 2018-03-08 | 2013.80 | 未披露 |
更多>>
from December 31, 2016 to December 31, 2017
Proceeds from common stock sold, net of underwriters' discounts and cost
Proceeds from the exercise of stock options
|
2017-12-31 |
| 2017-12-29 | 2013.07 | 未披露 | 定期报告 | 2017-12-27 |
| 2017-11-01 | 1739.77 | 未披露 | 定期报告 | 2017-10-27 |
| 2017-11-01 | 1738.58 | 未披露 |
更多>>
from December 31, 2016 to September 30, 2017
Proceeds from the exercise of stock options
Shares issued for option exercise - receivable
|
2017-09-30 |
| 2017-08-09 | 1736.44 | 未披露 | 定期报告 | 2017-08-03 |
| 2017-08-09 | 1736.07 | 未披露 |
更多>>
from December 31, 2016 to June 30, 2017
Proceeds from the exercise of stock options
|
2017-06-30 |
| 2017-05-08 | 1734.61 | 未披露 | 定期报告 | 2017-05-04 |
| 2017-04-21 | 1730.50 | 未披露 | 定期报告 | 2017-04-06 |
| 2017-05-08 | 1731.80 | 未披露 |
更多>>
from December 31, 2016 to March 31, 2017
Proceeds from the exercise of stock options
|
2017-03-31 |
| 2017-03-02 | 1726.59 | 未披露 | 定期报告 | 2017-02-24 |
| 2017-03-02 | 1724.68 | 未披露 |
更多>>
from December 31, 2015 to December 31, 2016
Exercise of stock options
Cancellation of common stock
|
2016-12-31 |
| 2016-08-09 | 1722.56 | 未披露 |
更多>>
From December 31, 2015 to June 30, 2016
Cancellation of common stock
|
2016-06-30 |
| 2015-11-09 | 1722.57 | 未披露 |
更多>>
from December 31, 2014 to September 30, 2015
Proceeds from common stock sold, net of underwriters' discounts and cost
Exercise of stock options
Cashless exercise of warrants
|
2015-09-30 |
| 2015-08-13 | 1718.99 | 未披露 |
更多>>
from December 31, 2014 to June 30, 2015
Proceeds from common stock sold, net of underwriters' discounts and cost
Exercise of stock options
Cashless exercise of warrants
|
2015-06-30 |
| 2015-05-08 | 1717.71 | 未披露 | 定期报告 | 2015-05-05 |
| 2015-04-13 | 1708.41 | 未披露 | 定期报告 | 2015-04-07 |
| 2015-05-08 | 1625.08 | 未披露 |
更多>>
from December 31, 2014 to March 31, 2015
Proceeds from common stock sold, net of underwriters' discounts and cost
Exercise of stock options
|
2015-03-31 |
| 2015-06-08 | 1069.53 | 未披露 |
更多>>
The Company effected a 1-for-5 reverse stock split of the Company’s common stock on July 11, 2014. All references to common stock, shares outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to condensed consolidated financial statements have been restated to reflect the 1-for-5 reverse stock split on a retroactive basis
|
2015-03-10 |
| 2015-03-12 | 1067.21 | 未披露 |
更多>>
from December 31, 2013 to December 31, 2014
Proceeds from common stock sold, net of costs
Issuance of common stock for business combination
Issuance of common stock in exchange for restricted stock units
Conversion of preferred stock to common stock
The Company effected a 1-for-5 reverse stock split of the Company’s common stock on July 11, 2014. All references to common stock, shares outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to condensed consolidated financial statements have been restated to reflect the 1-for-5 reverse stock split on a retroactive basis
|
2014-12-31 |
| 2014-11-17 | 1064.71 | 未披露 | 定期报告 | 2014-11-10 |
| 2014-11-17 | 868.81 | 未披露 |
更多>>
From December 31, 2013 to September 30, 2014
Issuance of common stock for cash
Issuance of common stock for business combination
Conversion of preferred stock to common stock
The Company effected a 1-for-5 reverse stock split of the Company’s common stock on July 11, 2014. All references to common stock, shares outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to condensed consolidated financial statements have been restated to reflect the 1-for-5 reverse stock split on a retroactive basis
|
2014-09-30 |
| 2014-08-14 | 868.81 | 未披露 | 定期报告 | 2014-08-11 |
| 2014-08-14 | 467.93 | 未披露 |
更多>>
The Company effected a 1-for-5 reverse stock split of the Company’s common stock on July 11, 2014. All references to common stock, shares outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to condensed consolidated financial statements have been restated to reflect the 1-for-5 reverse stock split on a retroactive basis
|
2014-07-14 |
| 2014-05-14 | 2339.63 | 未披露 |
更多>>
from January 1, 2014 to March 31, 2014
Proceeds from the sale of common stock at average price of $3.81 per share, net of offering costs
Preferred stock 220,000 shares converted to 2,200,000 Common stock shares
|
2014-03-31 |
| 2014-03-31 | 2339.63 | 未披露 | 定期报告 | 2014-03-24 |
| 2014-03-31 | 2073.39 | 22.00 |
更多>>
from December 31,2012 to December 31,2013
Proceeds from common stock sold (at a weighted average $2.62 per share) net of costs
Proceeds from preferred stock sold (at an average $25.00 per share) net of costs
|
2013-12-31 |
| 2013-11-12 | 2085.89 | 未披露 | 定期报告 | 2013-11-08 |
| 2013-11-12 | 2066.33 | 22.00 |
更多>>
from January 1, 2013 to September 30, 2013
Proceeds from the sale of preferred stock sold at $25.00 per share and common stock at $2.50 per share, net of offering costs
Proceeds from the sale of common stock at $3.30 per share, net of offering costs
|
2013-09-30 |
| 2013-05-10 | 1960.44 | 22.00 |
更多>>
from January 1, 2013 to March 31, 2013
Proceeds from the sale of preferred stock at $25.00 per share and common stock at $2.50 per share, net of offering costs.
|
2013-03-31 |
| 2012-11-13 | 1293.44 | 未披露 |
更多>>
from January 1, 2012 to August 2, 2012
Options exercised between January 1, 2012 and August 2, 2012
Shares issued in a cashless exercise of options
Shares issued in a cashless exercise of warrants
Warrants exercised from January 1, 2012 and September 30, 2012
Proceeds from common stock sold (at an average $12.45 per share), net of costs
|
2012-08-02 |
| 2012-08-09 | 1292.27 | 未披露 |
更多>>
from January 1, 2012 to June 30, 2012
Options exercised between January 1, 2012 and June 30, 2012
Shares issued in a cashless exercise of options
Warrants exercised from January 1, 2012 and June 30, 2012
Proceeds from common stock sold, net of costs
|
2012-06-30 |
| 2012-05-09 | 1248.63 | 未披露 | 定期报告 | 2012-05-07 |
| 2012-05-09 | 1244.46 | 未披露 |
更多>>
Options exercised between January 1, 2012 and March 31, 2012
|
2012-03-31 |
| 2011-11-14 | 1240.64 | 未披露 | 定期报告 | 2011-11-07 |
| 2011-11-14 | 1240.43 | 未披露 |
更多>>
from January 1, 2011 to September 30, 2011
Common Stock sold to fulfill over-allotment option from IPO at $6.00 per share, net of related costs
Warrants exercised between March 1, 2011 and August 31, 2011 from the 2010 Senior Convertible Notes at $5.73 per share
Additional shares issued in January 2011 in connection with the December 22, 2010 conversion of notes into common stock
Common stock issued in a public offering in July 19, 2011 at $10.00 per share, net of costs
|
2011-09-30 |
| 2011-08-15 | 1240.43 | 未披露 | 定期报告 | 2011-08-11 |
| 2011-08-15 | 722.92 | 未披露 |
更多>>
from January 1, 2011 to June 30, 2011
Common Stock issued to fulfill over-allotment option from IPO, net of related costs
Warrants exercised from the 2010 Senior Convertible Notes
Additional shares issued in connection with the December 22, 2010 conversion of notes into common stock
|
2011-06-30 |
| 2011-04-13 | 718.97 | 未披露 | 定期报告 | 2011-04-08 |
| 2011-05-16 | 718.97 | 未披露 | 定期报告 | 2011-03-31 |
| 2011-04-13 | 674.64 | 未披露 |
更多>>
from dec 31 2009 to dec 31 2010
Conversion of notes and accrued interest to common stock in December 2010
Common stock issued in IPO in December 2010, net of related costs
Common Stock issued to Licensor for amendment in December 2010
|
2010-12-31 |
From June 30,2025 to September 30,2025
Issuance of common stock upon exercise of stock options
Issuance of common stock, pre-funded warrants and warrants in an underwritten offering, net of issuance costs
Issuance of common stock upon exercise of warrants
Issuance of common stock for settlement of restricted stock units (RSUs)
Issuance of common stock and warrants in a private placement to a related party, net of issuance costs
From March 31, 2025 to June 30, 2025
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of common stock for settlement of restricted stock units (RSUs)
From December 31, 2024 to March 31, 2025
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
From December 31, 2023 to December 31, 2024
Issuance of common stock under ATM equity offering program, net of issuance costs
Issuance of common stock and warrants in private placements to a related party, net of issuance costs
Issuance of common stock for settlement of RSUs
Issuance of common stock and warrants in a registered direct offering, net of issuance costs
Issuance of common stock upon exercise of stock options
Issuance of common stock under ESPP
From June 30, 2024 to September 30, 2024
Issuance of common stock for settlement of restricted stock units (RSUs)
From March 31, 2024 to June 30, 2024
Issuance of common stock and warrants in a registered direct offering and a private placement, net of issuance costs
Issuance of common stock for settlement of restricted stock units (RSUs)
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of common stock upon exercise of stock options
1.Common stock offered 634,500 shares by the company
2.On June 17, 2024, Assembly Biosciences, Inc. entered into a Securities Purchase Agreement with Gilead Sciences, Inc. for the issuance and sale, in a private placement, of 179,500 shares of the Company’s common stock
Assembly Biosciences, Inc. today announced that it expects a 1-for-12 reverse stock split of its outstanding shares of common stock will be effective as of February 9, 2024. The company anticipates that its common stock will begin trading on a split-adjusted basis on The Nasdaq Global Select Market under the same symbol when the market opens on February 12, 2024.
From June 30, 2023 to September 30, 2023
Issuance of common stock for settlement of restricted stock units (RSUs)
From March 31, 2023 to June 30, 2023
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
Issuance of common stock for settlement of restricted stock units (RSUs)
From December 31, 2022 to March 31, 2023
Issuance of common stock for settlement of restricted stock units (RSUs)
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
From December 31, 2021 to December 31, 2022
Issuance of common stock under ATM equity offering program, net of issuance costs
Issuance of common stock under ESPP
Issuance of common stock for settlement of RSUs
From June 30, 2022 to September 30, 2022
Issuance of common stock for settlement of restricted stock units (RSUs)
From March 31, 2022 to June 30, 2022
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of common stock for settlement of restricted stock units (RSUs)
From December 31, 2021 to March 31, 2022
Issuance of common stock for settlement of restricted stock units (RSUs)
From December 31, 2020 to December 31, 2021
Issuance of common stock under ATM equity offering program, net of issuance costs
Issuance of common stock under ESPP
Issuance of common stock for settlement of RSUs
Issuance of common stock upon cashless exercise of pre-funded warrants
From June 30, 2021 to September 30, 2021
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
Issuance of common stock upon cashless exercise of pre-funded warrants
Issuance of common stock for settlement of restricted stock units (RSUs)
From March 31, 2021 to June 30, 2021
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
Issuance of common stock under ESPP
Issuance of common stock for settlement of restricted stock units (RSUs)
Issuance of common stock upon cashless exercise of pre-funded warrants
from December 31, 2020 to March 31, 2021
Issuance of common stock under at-the-market (ATM) equity offering program, net of issuance costs
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
From December 31,2019 to December 31,2020
Issuance of common stock upon exercise of stock options
Issuance of shares of common stock for settlement of RSUs
Sale of common stock, net of commissions and fees
Issuance of common stock under ESPP
From June 30, 2020 to September 30, 2020
Issuance of common stock upon exercise of stock options
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
From March 31, 2020 to June 30, 2020
Issuance of common stock upon exercise of stock options
Issuance of common stock under ESPP
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
From December 31, 2019 to March 31, 2020
Issuance of common stock upon exercise of stock options
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
from December 31, 2018 to December 31, 2019
Sale of common stock and pre-funded warrants, net of underwriters' discount and costs
Issuance of common stock upon exercise of stock options
Issuance of common stock under ESPP
Issuance of shares of common stock for settlement of RSUs
Assembly Biosciences, Inc. (Nasdaq: ASMB) (“Assembly”), today announced the closing of its previously announced underwritten public offering of 6,287,878 shares of its common stock to the public at $16.50 per share, which included the exercise in full by the underwriters of their option to purchase 1,136,363 additional shares of common stock.
from June 30, 2019 to September 30, 2019
Issuance of common stock upon exercise of stock options
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
From March 31, 2019 to June 30, 2019
Issuance of common stock upon exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Issuance of shares of common stock for settlement of restricted stock units (RSUs)
from December 31, 2018 to March 31, 2019
Proceeds from the exercise of stock options
Issuance of shares for settlement of restricted stock units
from December 31, 2017 to December 31, 2018
Proceeds from common stock sold, net of underwriters' discounts and cost
Proceeds from the exercise of stock options
Issuance of common stock under Employee Stock Purchase Plan (ESPP)
Settlement of restricted stock units into common stock
from December 31, 2017 to September 30, 2018
Proceeds from common stock sold, net of underwriters' discounts and cost
Proceeds from the exercise of stock options
Settlement of restricted stock units into common stock
from December 31, 2017 to June 30, 2018
Proceeds from the exercise of stock options
From December 31, 2017 to March 31, 2018
Proceeds from the exercise of stock options
from December 31, 2016 to December 31, 2017
Proceeds from common stock sold, net of underwriters' discounts and cost
Proceeds from the exercise of stock options
from December 31, 2016 to September 30, 2017
Proceeds from the exercise of stock options
Shares issued for option exercise - receivable
from December 31, 2016 to June 30, 2017
Proceeds from the exercise of stock options
from December 31, 2016 to March 31, 2017
Proceeds from the exercise of stock options
from December 31, 2015 to December 31, 2016
Exercise of stock options
Cancellation of common stock
From December 31, 2015 to June 30, 2016
Cancellation of common stock
from December 31, 2014 to September 30, 2015
Proceeds from common stock sold, net of underwriters' discounts and cost
Exercise of stock options
Cashless exercise of warrants
from December 31, 2014 to June 30, 2015
Proceeds from common stock sold, net of underwriters' discounts and cost
Exercise of stock options
Cashless exercise of warrants
from December 31, 2014 to March 31, 2015
Proceeds from common stock sold, net of underwriters' discounts and cost
Exercise of stock options
The Company effected a 1-for-5 reverse stock split of the Company’s common stock on July 11, 2014. All references to common stock, shares outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to condensed consolidated financial statements have been restated to reflect the 1-for-5 reverse stock split on a retroactive basis
from December 31, 2013 to December 31, 2014
Proceeds from common stock sold, net of costs
Issuance of common stock for business combination
Issuance of common stock in exchange for restricted stock units
Conversion of preferred stock to common stock
The Company effected a 1-for-5 reverse stock split of the Company’s common stock on July 11, 2014. All references to common stock, shares outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to condensed consolidated financial statements have been restated to reflect the 1-for-5 reverse stock split on a retroactive basis
From December 31, 2013 to September 30, 2014
Issuance of common stock for cash
Issuance of common stock for business combination
Conversion of preferred stock to common stock
The Company effected a 1-for-5 reverse stock split of the Company’s common stock on July 11, 2014. All references to common stock, shares outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to condensed consolidated financial statements have been restated to reflect the 1-for-5 reverse stock split on a retroactive basis
The Company effected a 1-for-5 reverse stock split of the Company’s common stock on July 11, 2014. All references to common stock, shares outstanding, average number of shares outstanding and per share amounts in these condensed consolidated financial statements and notes to condensed consolidated financial statements have been restated to reflect the 1-for-5 reverse stock split on a retroactive basis
from January 1, 2014 to March 31, 2014
Proceeds from the sale of common stock at average price of $3.81 per share, net of offering costs
Preferred stock 220,000 shares converted to 2,200,000 Common stock shares
from December 31,2012 to December 31,2013
Proceeds from common stock sold (at a weighted average $2.62 per share) net of costs
Proceeds from preferred stock sold (at an average $25.00 per share) net of costs
from January 1, 2013 to September 30, 2013
Proceeds from the sale of preferred stock sold at $25.00 per share and common stock at $2.50 per share, net of offering costs
Proceeds from the sale of common stock at $3.30 per share, net of offering costs
from January 1, 2013 to March 31, 2013
Proceeds from the sale of preferred stock at $25.00 per share and common stock at $2.50 per share, net of offering costs.
from January 1, 2012 to August 2, 2012
Options exercised between January 1, 2012 and August 2, 2012
Shares issued in a cashless exercise of options
Shares issued in a cashless exercise of warrants
Warrants exercised from January 1, 2012 and September 30, 2012
Proceeds from common stock sold (at an average $12.45 per share), net of costs
from January 1, 2012 to June 30, 2012
Options exercised between January 1, 2012 and June 30, 2012
Shares issued in a cashless exercise of options
Warrants exercised from January 1, 2012 and June 30, 2012
Proceeds from common stock sold, net of costs
Options exercised between January 1, 2012 and March 31, 2012
from January 1, 2011 to September 30, 2011
Common Stock sold to fulfill over-allotment option from IPO at $6.00 per share, net of related costs
Warrants exercised between March 1, 2011 and August 31, 2011 from the 2010 Senior Convertible Notes at $5.73 per share
Additional shares issued in January 2011 in connection with the December 22, 2010 conversion of notes into common stock
Common stock issued in a public offering in July 19, 2011 at $10.00 per share, net of costs
from January 1, 2011 to June 30, 2011
Common Stock issued to fulfill over-allotment option from IPO, net of related costs
Warrants exercised from the 2010 Senior Convertible Notes
Additional shares issued in connection with the December 22, 2010 conversion of notes into common stock
from dec 31 2009 to dec 31 2010
Conversion of notes and accrued interest to common stock in December 2010
Common stock issued in IPO in December 2010, net of related costs
Common Stock issued to Licensor for amendment in December 2010